Abdelmaksoud AHK, Abdelaziz AO, Nabeel MM, et al. - This study was intended to examine the treatment effectiveness and survival of hepatic arterial infusion chemotherapy (HAIC) for patients with advanced hepatocellular carcinoma (HCC) and portal vein tumour thrombosis (PVTT) with compensated cirrhosis in comparison with sorafenib as the standard of care therapy versus best supportive care (BSC). Researchers designed a case–control study including a total of 91 patients with advanced HCC and PVTT classified into three groups: Group 1 20 treated with HAIC, (50 mg adriamycin and 50 mg cisplatin were infused in hepatic artery); Group 2, 42 patients treated with BSC; and Group 3, 29 patients treated with sorafenib. The results indicate that in patients with advanced HCC and PVTT, HAIC was found to be a safe procedure with a better response rate and longer survival than best supportive care or sorafenib.